Diffuse Alveolar Damage (DAD), a severe pathological consequence of acute lung injury triggered by factors like infection or ...

Savara advances BLA plans with strong molgramostim data, large aPAP market potential, and a reinforced cash position. Find ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2025.

Macrophages are found in virtually all tissues of the body, including the blood, lymph nodes, spleen, lungs, brain, and bone.

A newly reported case study has documented a novel nonsense variant in the RTEL1 gene in a patient with familial pulmonary fibrosis (PF), adding to an expanding understanding of how telomere-related ...

Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Bristol Myers Squibb today announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell ...

The authors investigated the epigenetic mechanisms regulating the differentiation of circulating monocytes that infiltrate the CNS and adopt microglia-like characteristics. The work is useful to the ...

Savara Inc. (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings and ...